-Data underlie the ongoing clinical advance of MT-302, the world’s first in vivo mRNA CAR drug development candidate- -Myeloid also highlights its pioneering CRISPR-Enabled Autonomous Transposable Element (CREATE) platform technology for precision, RNA-mediated gene editing and delivery- CAMBRIDGE, Mass, May 7, 2024 – Myeloid Therapeutics, Inc. (“Myeloid”), a clinical stage immunology company, today announced multiple […]